Anesthesia is a condition in which there is a reversible blockage in the electrical and chemical signals that passes information to the brain, resulting in loss of sensation. Medications known to result from anesthesia are called anesthetics. Anesthetics are commonly used to facilitate medical and surgical procedures in order to prevent discomfort and pain. The major end-points (effects) that are expected to be achieved through anesthetics are unconsciousness, amnesia, analgesia, and muscle relaxation. Several drugs may be needed in combination if the goal is to achieve multiple endpoints at the same time or in stages.
Anesthesia has several risks and complications associated with it such as pulmonary distress, heart attack, pulmonary embolism along minor risks such as postoperative nausea and vomiting or PONV. There is currently a significant shortage of anesthetics in several parts of the world. The American Association of Anesthesiologists (ASA) noted a considerable shortage of vital anesthetic drugs such as propofol, succinylcholine, even epinephrine in the past few years.
There are two types of drugs namely, local anesthetic and general anesthetic. Local anesthesia is delivered to block pain in a specific body part, generally used for dental treatment, stitching, skin biopsies, and several minimally invasive procedures.
On the other hand, the use of general anesthesia includes more extensive surgical procedures. Several advantages offered by general anesthesia are control of the body process mainly respiratory and circulatory system allows motionless for long duration during surgery and allows operation on different body parts at a time.
The rise in the number of surgeries, the aging population and use in pediatrics are the key drivers for the global anesthesia drugs market. U.S.A alone contributes around US$ 3.5 billion markets. Around 60-70% of the market share is of intravenous anesthetic in the U.S. market. Diprivan (Propofol) from Astra Zeneca, Lusedra (for propofol disodium) from Eisai Co. ltd., SUPREME (desflurane, USP) and AERRANE (isoflurane, USP) from Baxter are few of the top leading brands.
Ketamine is an anesthetic drug reported to be one of the long-time existing drugs in the market. JHP Pharma offers a branded generic of ketamine known as Ketalar, which remains the top-selling brand among general anesthesia.
Anesthetics drugs market largely consists of major pharmaceutical companies, niche pain management, and generic anesthesia drug suppliers. Top leading players in the anesthesia drugs market are Baxter, Abbott Laboratories, AstraZeneca PLC, Eisai Co. Ltd following Claris Life Sciences, Merck and Co., Celgene Corporation, Roche Diagnostics, and Piramal Healthcare. Merck is currently struggling to introduce sugammadex facing the third rejection by the FDA.
With the increasing demand for anesthetic drugs in the market worldwide, most of the companies R&D (Research & Development) activities are focused on reducing the number of side effects associated with existing anesthetic drugs. Several gender-based anesthesia drugs are also being introduced into the market to cater to challenges physiologically linked with both sexes.
The below mentioned quantitative and qualitative analysis is subject to enhancement and refinement during the course of research.
The report analyses and estimates the market by:
- Product Segment/Sub-segment Types
- Market Share Analysis, segments, players, geographies
- Geographic Analysis
- Market Segmentation
- Treatment Algorithm – Region-specific
- Drivers & inhibitors in the market
- Opportunities in the market
- Reimbursement scenario – Region-specific
- Pipeline developments – by phases
- Competitive landscape – recent strategic developments
Know More @ https://hmsdesk.com/pharmacy-systems.php